RNAi Therapeutics Market 2027 by Molecule Type, Application, Route of Administration, End User and Geography | The Insight Partners

RNAi Therapeutics Market to 2027 - Global Analysis and Forecasts By Molecule Type (Small Interfering RNAs (siRNA), MicroRNA (miRNA)); Application (Genetic Disorders, Oncology, Neurodegenerative Disorders, Cardiovascular, Respiratory Disorders, Infectious Diseases, Renal Diseases, Other); Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections, Others); End User (Diagnostic Laboratories, Research and Academic Laboratories, Hospitals) and Geography

Report Code: TIPRE00007157 | No. of Pages: 150 | Category: Biotechnology | Status: Upcoming
MARKET INTRODUCTION

RNA interference is a biological method in which molecules of RNA inhibit gene expression by neutralizing the targeted mRNA molecules. This method plays vital role in defending cells against virus. This technique is an innovative method which into the clinical trial phase, and various companies are seeking for the FDA and EU commission approval for their products and technologies. The RNAi therapeutic are formulated to treat diseases such as cancer, haemophilia, age related diseases, and others.

MARKET DYNAMICS

The RNAi therapeutics market is forecasted to grow due to the key factors such as rising chronic diseases such as cancer, genetic disorders, and cardiovascular diseases among others. The growth of the market is also expected to grow due to rising technological development and growing FDA approvals for RNAi therapeutics. The growth of the market is expected to have growth opportunities in the emerging nations were healthcare facilities and developments are rising significantly.

MARKET SCOPE

The "Global RNAi Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the biotechnology industry with a special focus on the global market trend analysis. The report aims to provide an overview of RNAi therapeutics market with detailed market segmentation by molecule type, application, route of administration, end user and geography. The global RNAi therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading RNAi therapeutics market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global RNAi Therapeutics market is segmented on the basis of molecule type, application, route of administration, and end user. Based on the molecule type the market is segmented as small interfering RNAs (siRNA), and microRNA (miRNA). On the basis of application the market is classified as genetic disorders, oncology, neurodegenerative disorders, cardiovascular, respiratory disorders, infectious diseases, renal diseases, and others. Based on the route of administration the market is categorized as intradermal injections, pulmonary delivery, intravenous injections, intraperitoneal injections, and others. And on the basis of end user the market is divided into diagnostic laboratories, research and academic laboratories, and hospitals


REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global RNAi therapeutics market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The RNAi therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting RNAi therapeutics market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the RNAi therapeutics market in these regions.


MARKET PLAYERS

The reports cover key developments in the RNAi therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from RNAi therapeutics market are anticipated to lucrative growth opportunities in the future with the rising demand for RNAi therapeutics market in the global market. Below mentioned is the list of few companies engaged in the RNAi therapeutics market.

The report also includes the profiles of key RNAi therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  Alnylam Pharmaceuticals, Inc.
  •  Sanofi
  •  OLIX PHARMACEUTICALS, INC.
  •  GlaxoSmithKline plc
  •  Benitec Biopharma
  •  Arbutus Biopharma Corporation
  •  Silence Therapeutics
  •  Rexahn Pharmaceuticals, Inc
  •  F. Hoffmann-La Roche Ltd
  •  Quark

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 RNAi Therapeutics Market - By Molecule Type
1.3.2 RNAi Therapeutics Market - By Application
1.3.3 RNAi Therapeutics Market - By Route of Administration
1.3.4 RNAi Therapeutics Market - By End User
1.3.5 RNAi Therapeutics Market - By Region
1.3.5.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. RNAI THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. RNAI THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. RNAI THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. RNAI THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. RNAI THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. RNAI THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - MOLECULE TYPE
7.1. OVERVIEW
7.2. MOLECULE TYPE MARKET FORECASTS AND ANALYSIS
7.3. SMALL INTERFERING RNAS (SIRNA)
7.3.1. Overview
7.3.2. Small Interfering RNAs (siRNA) Market Forecast and Analysis
7.4. MICRORNA (MIRNA)
7.4.1. Overview
7.4.2. MicroRNA (miRNA) Market Forecast and Analysis
8. RNAI THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. GENETIC DISORDERS
8.3.1. Overview
8.3.2. Genetic Disorders Market Forecast and Analysis
8.4. ONCOLOGY
8.4.1. Overview
8.4.2. Oncology Market Forecast and Analysis
8.5. NEURODEGENERATIVE DISORDERS
8.5.1. Overview
8.5.2. Neurodegenerative Disorders Market Forecast and Analysis
8.6. CARDIOVASCULAR
8.6.1. Overview
8.6.2. Cardiovascular Market Forecast and Analysis
8.7. RESPIRATORY DISORDERS
8.7.1. Overview
8.7.2. Respiratory Disorders Market Forecast and Analysis
8.8. INFECTIOUS DISEASES
8.8.1. Overview
8.8.2. Infectious Diseases Market Forecast and Analysis
8.9. RENAL DISEASES
8.9.1. Overview
8.9.2. Renal Diseases Market Forecast and Analysis
8.10. OTHER
8.10.1. Overview
8.10.2. Other Market Forecast and Analysis
9. RNAI THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - ROUTE OF ADMINISTRATION
9.1. OVERVIEW
9.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
9.3. INTRADERMAL INJECTIONS
9.3.1. Overview
9.3.2. Intradermal Injections Market Forecast and Analysis
9.4. PULMONARY DELIVERY
9.4.1. Overview
9.4.2. Pulmonary Delivery Market Forecast and Analysis
9.5. INTRAVENOUS INJECTIONS
9.5.1. Overview
9.5.2. Intravenous Injections Market Forecast and Analysis
9.6. INTRAPERITONEAL INJECTIONS
9.6.1. Overview
9.6.2. Intraperitoneal Injections Market Forecast and Analysis
9.7. OTHERS
9.7.1. Overview
9.7.2. Others Market Forecast and Analysis
10. RNAI THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - END USER
10.1. OVERVIEW
10.2. END USER MARKET FORECASTS AND ANALYSIS
10.3. DIAGNOSTIC LABORATORIES
10.3.1. Overview
10.3.2. Diagnostic Laboratories Market Forecast and Analysis
10.4. RESEARCH AND ACADEMIC LABORATORIES
10.4.1. Overview
10.4.2. Research and Academic Laboratories Market Forecast and Analysis
10.5. HOSPITALS
10.5.1. Overview
10.5.2. Hospitals Market Forecast and Analysis
11. RNAI THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA
11.1.1 North America RNAi Therapeutics Market Overview
11.1.2 North America RNAi Therapeutics Market Forecasts and Analysis
11.1.3 North America RNAi Therapeutics Market Forecasts and Analysis - By Molecule Type
11.1.4 North America RNAi Therapeutics Market Forecasts and Analysis - By Application
11.1.5 North America RNAi Therapeutics Market Forecasts and Analysis - By Route of Administration
11.1.6 North America RNAi Therapeutics Market Forecasts and Analysis - By End User
11.1.7 North America RNAi Therapeutics Market Forecasts and Analysis - By Countries
11.1.7.1 United States RNAi Therapeutics Market
11.1.7.1.1 United States RNAi Therapeutics Market by Molecule Type
11.1.7.1.2 United States RNAi Therapeutics Market by Application
11.1.7.1.3 United States RNAi Therapeutics Market by Route of Administration
11.1.7.1.4 United States RNAi Therapeutics Market by End User
11.1.7.2 Canada RNAi Therapeutics Market
11.1.7.2.1 Canada RNAi Therapeutics Market by Molecule Type
11.1.7.2.2 Canada RNAi Therapeutics Market by Application
11.1.7.2.3 Canada RNAi Therapeutics Market by Route of Administration
11.1.7.2.4 Canada RNAi Therapeutics Market by End User
11.1.7.3 Mexico RNAi Therapeutics Market
11.1.7.3.1 Mexico RNAi Therapeutics Market by Molecule Type
11.1.7.3.2 Mexico RNAi Therapeutics Market by Application
11.1.7.3.3 Mexico RNAi Therapeutics Market by Route of Administration
11.1.7.3.4 Mexico RNAi Therapeutics Market by End User
11.2. EUROPE
11.2.1 Europe RNAi Therapeutics Market Overview
11.2.2 Europe RNAi Therapeutics Market Forecasts and Analysis
11.2.3 Europe RNAi Therapeutics Market Forecasts and Analysis - By Molecule Type
11.2.4 Europe RNAi Therapeutics Market Forecasts and Analysis - By Application
11.2.5 Europe RNAi Therapeutics Market Forecasts and Analysis - By Route of Administration
11.2.6 Europe RNAi Therapeutics Market Forecasts and Analysis - By End User
11.2.7 Europe RNAi Therapeutics Market Forecasts and Analysis - By Countries
11.2.7.1 Germany RNAi Therapeutics Market
11.2.7.1.1 Germany RNAi Therapeutics Market by Molecule Type
11.2.7.1.2 Germany RNAi Therapeutics Market by Application
11.2.7.1.3 Germany RNAi Therapeutics Market by Route of Administration
11.2.7.1.4 Germany RNAi Therapeutics Market by End User
11.2.7.2 France RNAi Therapeutics Market
11.2.7.2.1 France RNAi Therapeutics Market by Molecule Type
11.2.7.2.2 France RNAi Therapeutics Market by Application
11.2.7.2.3 France RNAi Therapeutics Market by Route of Administration
11.2.7.2.4 France RNAi Therapeutics Market by End User
11.2.7.3 Italy RNAi Therapeutics Market
11.2.7.3.1 Italy RNAi Therapeutics Market by Molecule Type
11.2.7.3.2 Italy RNAi Therapeutics Market by Application
11.2.7.3.3 Italy RNAi Therapeutics Market by Route of Administration
11.2.7.3.4 Italy RNAi Therapeutics Market by End User
11.2.7.4 Spain RNAi Therapeutics Market
11.2.7.4.1 Spain RNAi Therapeutics Market by Molecule Type
11.2.7.4.2 Spain RNAi Therapeutics Market by Application
11.2.7.4.3 Spain RNAi Therapeutics Market by Route of Administration
11.2.7.4.4 Spain RNAi Therapeutics Market by End User
11.2.7.5 United Kingdom RNAi Therapeutics Market
11.2.7.5.1 United Kingdom RNAi Therapeutics Market by Molecule Type
11.2.7.5.2 United Kingdom RNAi Therapeutics Market by Application
11.2.7.5.3 United Kingdom RNAi Therapeutics Market by Route of Administration
11.2.7.5.4 United Kingdom RNAi Therapeutics Market by End User
11.3. ASIA-PACIFIC
11.3.1 Asia-Pacific RNAi Therapeutics Market Overview
11.3.2 Asia-Pacific RNAi Therapeutics Market Forecasts and Analysis
11.3.3 Asia-Pacific RNAi Therapeutics Market Forecasts and Analysis - By Molecule Type
11.3.4 Asia-Pacific RNAi Therapeutics Market Forecasts and Analysis - By Application
11.3.5 Asia-Pacific RNAi Therapeutics Market Forecasts and Analysis - By Route of Administration
11.3.6 Asia-Pacific RNAi Therapeutics Market Forecasts and Analysis - By End User
11.3.7 Asia-Pacific RNAi Therapeutics Market Forecasts and Analysis - By Countries
11.3.7.1 Australia RNAi Therapeutics Market
11.3.7.1.1 Australia RNAi Therapeutics Market by Molecule Type
11.3.7.1.2 Australia RNAi Therapeutics Market by Application
11.3.7.1.3 Australia RNAi Therapeutics Market by Route of Administration
11.3.7.1.4 Australia RNAi Therapeutics Market by End User
11.3.7.2 China RNAi Therapeutics Market
11.3.7.2.1 China RNAi Therapeutics Market by Molecule Type
11.3.7.2.2 China RNAi Therapeutics Market by Application
11.3.7.2.3 China RNAi Therapeutics Market by Route of Administration
11.3.7.2.4 China RNAi Therapeutics Market by End User
11.3.7.3 India RNAi Therapeutics Market
11.3.7.3.1 India RNAi Therapeutics Market by Molecule Type
11.3.7.3.2 India RNAi Therapeutics Market by Application
11.3.7.3.3 India RNAi Therapeutics Market by Route of Administration
11.3.7.3.4 India RNAi Therapeutics Market by End User
11.3.7.4 Japan RNAi Therapeutics Market
11.3.7.4.1 Japan RNAi Therapeutics Market by Molecule Type
11.3.7.4.2 Japan RNAi Therapeutics Market by Application
11.3.7.4.3 Japan RNAi Therapeutics Market by Route of Administration
11.3.7.4.4 Japan RNAi Therapeutics Market by End User
11.3.7.5 South Korea RNAi Therapeutics Market
11.3.7.5.1 South Korea RNAi Therapeutics Market by Molecule Type
11.3.7.5.2 South Korea RNAi Therapeutics Market by Application
11.3.7.5.3 South Korea RNAi Therapeutics Market by Route of Administration
11.3.7.5.4 South Korea RNAi Therapeutics Market by End User
11.4. MIDDLE EAST AND AFRICA
11.4.1 Middle East and Africa RNAi Therapeutics Market Overview
11.4.2 Middle East and Africa RNAi Therapeutics Market Forecasts and Analysis
11.4.3 Middle East and Africa RNAi Therapeutics Market Forecasts and Analysis - By Molecule Type
11.4.4 Middle East and Africa RNAi Therapeutics Market Forecasts and Analysis - By Application
11.4.5 Middle East and Africa RNAi Therapeutics Market Forecasts and Analysis - By Route of Administration
11.4.6 Middle East and Africa RNAi Therapeutics Market Forecasts and Analysis - By End User
11.4.7 Middle East and Africa RNAi Therapeutics Market Forecasts and Analysis - By Countries
11.4.7.1 South Africa RNAi Therapeutics Market
11.4.7.1.1 South Africa RNAi Therapeutics Market by Molecule Type
11.4.7.1.2 South Africa RNAi Therapeutics Market by Application
11.4.7.1.3 South Africa RNAi Therapeutics Market by Route of Administration
11.4.7.1.4 South Africa RNAi Therapeutics Market by End User
11.4.7.2 Saudi Arabia RNAi Therapeutics Market
11.4.7.2.1 Saudi Arabia RNAi Therapeutics Market by Molecule Type
11.4.7.2.2 Saudi Arabia RNAi Therapeutics Market by Application
11.4.7.2.3 Saudi Arabia RNAi Therapeutics Market by Route of Administration
11.4.7.2.4 Saudi Arabia RNAi Therapeutics Market by End User
11.4.7.3 U.A.E RNAi Therapeutics Market
11.4.7.3.1 U.A.E RNAi Therapeutics Market by Molecule Type
11.4.7.3.2 U.A.E RNAi Therapeutics Market by Application
11.4.7.3.3 U.A.E RNAi Therapeutics Market by Route of Administration
11.4.7.3.4 U.A.E RNAi Therapeutics Market by End User
11.5. SOUTH AND CENTRAL AMERICA
11.5.1 South and Central America RNAi Therapeutics Market Overview
11.5.2 South and Central America RNAi Therapeutics Market Forecasts and Analysis
11.5.3 South and Central America RNAi Therapeutics Market Forecasts and Analysis - By Molecule Type
11.5.4 South and Central America RNAi Therapeutics Market Forecasts and Analysis - By Application
11.5.5 South and Central America RNAi Therapeutics Market Forecasts and Analysis - By Route of Administration
11.5.6 South and Central America RNAi Therapeutics Market Forecasts and Analysis - By End User
11.5.7 South and Central America RNAi Therapeutics Market Forecasts and Analysis - By Countries
11.5.7.1 Brazil RNAi Therapeutics Market
11.5.7.1.1 Brazil RNAi Therapeutics Market by Molecule Type
11.5.7.1.2 Brazil RNAi Therapeutics Market by Application
11.5.7.1.3 Brazil RNAi Therapeutics Market by Route of Administration
11.5.7.1.4 Brazil RNAi Therapeutics Market by End User
11.5.7.2 Argentina RNAi Therapeutics Market
11.5.7.2.1 Argentina RNAi Therapeutics Market by Molecule Type
11.5.7.2.2 Argentina RNAi Therapeutics Market by Application
11.5.7.2.3 Argentina RNAi Therapeutics Market by Route of Administration
11.5.7.2.4 Argentina RNAi Therapeutics Market by End User
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. RNAI THERAPEUTICS MARKET, KEY COMPANY PROFILES
13.1. ALNYLAM PHARMACEUTICALS, INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. SANOFI
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. OLIX PHARMACEUTICALS, INC.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. GLAXOSMITHKLINE PLC.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. BENITEC BIOPHARMA
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. ARBUTUS BIOPHARMA CORPORATION
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. SILENCE THERAPEUTICS
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. REXAHN PHARMACEUTICALS, INC
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. F. HOFFMANN-LA ROCHE LTD
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. QUARK
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. Alnylam Pharmaceuticals, Inc.
2. Sanofi
3. OLIX PHARMACEUTICALS, INC.
4. GlaxoSmithKline plc
5. Benitec Biopharma
6. Arbutus Biopharma Corporation
7. Silence Therapeutics
8. Rexahn Pharmaceuticals, Inc
9. F. Hoffmann-La Roche Ltd
10. Quark